 |
|
|
| |
Association of HDV RNA levels with liver disease progression in a
large cohort of treatment-naïve Asian patients with chronic hepatitis D
|
| |
| |
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) - (05/26/26)
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial - (04/17/26)
CROI: Efficacy and Safety of Long-Term Bulevirtide in Chronic Hepatitis Delta: Final Results From the Phase 3 MYR301 Study, Including 2 Participants With HIV/HBV/HDV Coinfection - (02/26/26)
EASL 2026 May 26-30 Barcelona
Habiba Kamal1,2,3, Ganbolor Jargalsaikhan4,5, Sanjaasuren Enkhtaivan4,5, Karin Lindahl1,2, Bekhbold Dashtseren4,5, Oyungerel Lkhagva-Ochir4,5, TuvshinjargalUlziibadrakh4,5, Andreas Bungert4,5, Elisabetta Degasperi3,6, Pietro Lampertico3,6,7, Heiner Wedemeyer3,8,9,10, Naranjargal B Dashdorj4,5 and Soo Aleman1,2,3
|
| |
|
|
|
|
|
